HNC364 vs Rasagiline (Azilect)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: MAO-B · full Parkinson's Disease pipeline
HNC364
Developed by Guangzhou Henovcom Bioscience Co. Ltd.
NCT05523570 · Phase 1 · completed
Participants were not randomized and neither they nor the investigators were blinded, and there was no placebo or comparator group, so this design cannot separate a real drug effect from chance, natural variation, or expectation. Results have not yet been posted.
Next expected readout: December 2026 · NCT06798519 (registry estimate)
No aligned efficacy figure on record for this race.
Rasagiline (Azilect)
Marketed by Teva Pharmaceutical Industries and partners
NCT01479530 · Phase 3 · completed
This was a randomized, triple-blind, placebo-controlled trial with 321 participants, with 158 assigned to placebo and 163 to rasagiline. The primary clinical endpoint—change in daily OFF time—favored rasagiline and was statistically significant (p=0.0228).
Reported efficacy
Change From Baseline in Mean Total Daily OFF Time Using Parkinson's Disease Patient Diary (Baseline and Weeks 4, 8, 12, and 16): Change From Baseline in Mean Total Daily OFF Time Using Parkinson's Disease Patient Diary (Baseline and Weeks 4, 8, 12, and 16): Azilect® -1.25 hours (Standard Error 0.16) vs Placebo -0.76 hours (Standard Error 0.16) (met)
Result source: NCT01479530
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | HNC364 | Rasagiline (Azilect) |
|---|---|---|
| OFF time, change | —Not reported | -1.3 vs -0.8−0.5 vs placeboNCT014795301 other result
|
| ON time without troublesome dyskinesia, change | —Not reported | —Not posted · NCT00203034 |
| UPDRS Part III, change | —Not reported | —Not posted · NCT00203034 |
| MDS-UPDRS Part II, change | —Not reported | 0.1 vs 2.3−2.2 vs placeboNCT023377252 other results
|
OFF time, change
- HNC364
- —Not reported
- Rasagiline (Azilect)
- -1.3 vs -0.8−0.5 vs placeboNCT01479530
1 other result
- -1.6 vs -1.2 NCT01268891
ON time without troublesome dyskinesia, change
- HNC364
- —Not reported
- Rasagiline (Azilect)
- —Not posted · NCT00203034
UPDRS Part III, change
- HNC364
- —Not reported
- Rasagiline (Azilect)
- —Not posted · NCT00203034
MDS-UPDRS Part II, change
- HNC364
- —Not reported
- Rasagiline (Azilect)
- 0.1 vs 2.3−2.2 vs placeboNCT02337725
2 other results
- -0.3 vs 1.0 NCT02337738
- -0.3 vs 1.0 NCT02337738
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
HNC364: no structured comparison results are available for Parkinson's Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. HNC364: 0 of 4 rows · Rasagiline (Azilect): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Rasagiline (Azilect) |
|---|---|
| Dropout rate | 7.4%a NCT01479530 · Phase 3 · Parkinson's Disease · phase 3 show 7 more results12.1% NCT01268891 · Phase 3 · Parkinson's Disease · phase 3 27%1 mg NCT02337764 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 11.6%1 mg NCT02337751 · Phase 3 · registry result, not featured evidence 15.5%1 mg NCT02337751 · Phase 3 · registry result, not featured evidence · combination 6.8%1 mg NCT02337725 · Phase 3 · registry result, not featured evidence 20.2%1 mg NCT02337738 · Phase 2/3 · registry result, not featured evidence 22.4%0.5 mg NCT02337738 · Phase 2/3 · registry result, not featured evidence |
| Discontinued due to AEs | 3.7%a NCT01479530 · Phase 3 · Parkinson's Disease · phase 3 show 7 more results10.6% NCT01268891 · Phase 3 · Parkinson's Disease · phase 3 20.7%1 mg NCT02337764 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 2.1%1 mg NCT02337751 · Phase 3 · registry result, not featured evidence 2.9%1 mg NCT02337751 · Phase 3 · registry result, not featured evidence · combination —1 mg NCT02337725 · Phase 3 · registry result, not featured evidence 16.3%1 mg NCT02337738 · Phase 2/3 · registry result, not featured evidence 13.4%0.5 mg NCT02337738 · Phase 2/3 · registry result, not featured evidence |
| Serious AEs | 4.3%a NCT01479530 · Phase 3 · Parkinson's Disease · phase 3 show 7 more results7.6% NCT01268891 · Phase 3 · Parkinson's Disease · phase 3 17.6%1 mg NCT02337764 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 4.2%1 mg NCT02337751 · Phase 3 · registry result, not featured evidence 5.1%1 mg NCT02337751 · Phase 3 · registry result, not featured evidence · combination 3.4%1 mg NCT02337725 · Phase 3 · registry result, not featured evidence 7.8%1 mg NCT02337738 · Phase 2/3 · registry result, not featured evidence 7.5%0.5 mg NCT02337738 · Phase 2/3 · registry result, not featured evidence |
| Most frequent reported AEs | show 7 more resultsdyskinesia 12.1% (placebo 7.6%) dizziness 6.1% (placebo 1.5%) dyspnoea 6.1% (placebo 0%) NCT01268891 · Phase 3 · Parkinson's Disease · phase 3 1 mg fall 16.7% nasopharyngitis 14% dyskinesia 10.8% NCT02337764 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 1 mg nasopharyngitis 17.9% fall 6.3% contusion 5.3% NCT02337751 · Phase 3 · registry result, not featured evidence 1 mg nasopharyngitis 26.5% fall 9.4% eczema 7.7% NCT02337751 · Phase 3 · registry result, not featured evidence · combination 1 mg nasopharyngitis 15.4% (placebo 15.1%) fall 5.1% (placebo 5.6%) NCT02337725 · Phase 3 · registry result, not featured evidence 1 mg dyskinesia 15.5% (placebo 7.1%) nasopharyngitis 14.7% (placebo 9.2%) fall 13.2% (placebo 5.7%) NCT02337738 · Phase 2/3 · registry result, not featured evidence 0.5 mg nasopharyngitis 18% (placebo 9.2%) fall 9.8% (placebo 5.7%) dyskinesia 8.3% (placebo 7.1%) NCT02337738 · Phase 2/3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 5 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Rasagiline (Azilect)
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 2 more results
show 2 more results
+ 2 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HNC364's landscape · Rasagiline (Azilect)'s landscape